Trial intelligence / Profile preview

Azzalure for Lateral Canthal Lines (Crow's Feet)

NCT01308060Phase 3Completed

Sponsor
Galderma
Start
Jan 2011
Primary completion
May 2012
Modality
Recombinant Proteins and Enzymes
01

Overview

A Phase 3 trial of botulinum toxin type A in lateral canthal rhytides, sponsored by Galderma. Started Jan 2011; status: completed.

02

Drugs

botulinum toxin type A
03

Conditions

lateral canthal rhytides

Beyond the preview

Go deeper on NCT01308060.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01308060.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call